Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits-Reference-Cited by-同舟云学术

Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits

Published:2022-08-12 Issue:17 Volume:65 Page:11607-11632
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Das Nirmal¹²,Bandopadhyay Purbita³²,Roy Swarnali¹,Sinha Bishnu Prasad³²,Dastidar Uddipta Ghosh¹²,Rahaman Oindrila³,Pal Sourav¹²,Ganguly Dipyaman³²,Talukdar Arindam¹²^ORCID

Affiliation:

1. Department of Organic and Medicinal Chemistry, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata 700032, West Bengal, India

2. Academy of Scientific and Innovative Research, Ghaziabad 201002, India

3. IICB-Translational Research Unit of Excellence, Department of Cancer Biology and Inflammatory Disorders, CSIR-Indian Institute of Chemical Biology, CN6, Sector V, Salt Lake, Kolkata 700091, West Bengal, India

Funder

Indian Council of Medical Research

Council of Scientific and Industrial Research

University Grants Commission

Department of Science and Technology, Ministry of Science and Technology, India

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00386

Reference76 articles.